LV11736B - Novel 8-substituted-2-amino-tetralines - Google Patents

Novel 8-substituted-2-amino-tetralines Download PDF

Info

Publication number
LV11736B
LV11736B LVP-96-420A LV960420A LV11736B LV 11736 B LV11736 B LV 11736B LV 960420 A LV960420 A LV 960420A LV 11736 B LV11736 B LV 11736B
Authority
LV
Latvia
Prior art keywords
formula
compound
alkyl
aryl
hydrogen
Prior art date
Application number
LVP-96-420A
Other languages
English (en)
Other versions
LV11736A (lv
Inventor
Anden Nils-Erik
Backlund Hiik Berit C Elisabet
Bjirk Anna Lena Maria
Hacksell Uli Alf
Hillver Sven-Erik
Liu Ye
Mellin Eva Charlotta
Persson Eva Marie
Vallgarda Karl Jerk
Yu Hong
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of LV11736A publication Critical patent/LV11736A/lv
Publication of LV11736B publication Critical patent/LV11736B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Polyamides (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (10)

  1. LV 11736 IZGUDROJUMA FORMULA
    kur 15 R ir ūdeņradis vai metilgrupa ar nosacījumu, ka Crmetilaizvietotājs ir cis konfigurācijā, Z ir ūdeņradis vai halogēns, 20 25 Q ir COR1 vai 5- vai 6-locekļu arilcikls, kas var saturēt 1 vai 2 heteroatomus, kas izvēlēti no N, O vai S, un ir vai nu (i) neobligāti aizvietots ar vienu vai vairākiem aizvietotājiem, kas neatkarīgi izvēlēti no halogēna, CN, CF3, Cļ-Cealkilgrupas, C2-C6alke-nilgrupas vai zemākas alkoksigrupas, vai ir (ii) piesaistīts arilciklam pie diviem blakus esošiem oglekļa atomiem, pie kam minētais arilcikls ir neobligāti aizvietots ar vienu vai vairākiem aizvietotājiem, kas neatkarīgi izvēlēti no halogēna, CN, CF3, CrC6alkilgrupas, C2-C6alkenilgrupas vai zemākas alkoksigrupas, 30 R1 ir Cļ-Cgalkilgrupa vai 5- vai 6-locekļu aromātisks cikls, kas var saturēt heteroatomus, kas izvēlēti no O un S, un ir vai nu (i) neobligāti aizvietots ar aizvietotājiem, kas neatkarīgi izvēlēti no halogēna, CF3, zemākās alkilgrupas vai zemākas alkoksigrupas vai ir (ii) piesaistīts benzilciklam pie diviem blakus esošiem oglekļa atomiem, pie kam minētais benzilcikls neobligāti ir aizvietots ar aizvietotājiem, kas neatkarīgi izvēlēti no halogēna, CF3, zemākas alkilgrupas vai zemākas alkoksigrupas, R2 ir ūdeņradis vai C^Cgalkilgrupa, R3 ir C,-C6alkilgrupa, 35 5 2 "(CH2)a-R4, -CH2-CH=CH-(CH2)b-R4, -CH2-C=C-(CH2)b-R4, 5 2 (CH2)c
    (CH2)b-R4 (CH2)
    (CH2)d kur 10 15 20 a ir 1 līdz 5, b ir 0, 1 vai 2, c ir 1,2, 3 vai 4, d ir 2 vai 3, X ir O, S vai NR5, kur Rs ir ūdeņradis, cikloalkilgrupa, alkilgrupa, Cļ-Csalkilgrupa, neobligāti aizvietota ar hidroksigrupu, aminogrupu, alkilaminogrupu, dialkilaminogrupu, arilgrupu, heteroarilgrupu, aralkilgrupu, alkoksi-karbonilgrupu, alkilsulfonilgrupu, fenilsulfonilgrupu, tolilsulfo-nilgrupu, benzilsulfonilgrupu, formilgrupu, karbamoilgrupu vai sulfamoilgrupu, R4 ir ūdeņradis, halogēns, CF3, zemāka alkilgrupa, CN vai grupa -ORs, -COOR7, -CONR8R9, -S02NR8R9, -SOmR10, -NR11R12, 25
    (CH2>c vai -CH (CH 30 kur c, d un X ir ar iepriekš doto nozīmi, A ir ūdeņradis, alkilsulfonilgrupa, fenilsulfonilgrupa, tolilsulfonilgrupa, benzilsulfonilgrupa, acilgrupa vai alkoksikarbonilgrupa, R6 ir ūdeņradis, alkilgrupa, alkenilgrupa, cikloalkilgrupa, arilgrupa, 35 aralkilgrupa, acilgrupa, alkoksikarbonilgrupa, 3 LV 11736 R7 ir ūdeņradis, alkilgrupa, alkenilgrupa, arilgrupa vai aralkilgrupa, R8 un R9, kas ir vienādi vai dažādi, katrs ir ūdeņradis, alkilgrupa, arilgrupa vai aralkilgrupa, R10 ir alkilgrupa, cikloalkilgrupa, arilgrupa vai aralkilgrupa un arilatlikums var būt aizvietots ar halogēnu, ciāngrupu, alkilgrupu, alkoksigrupu, trifluormetilgrupu vai trifluormetoksigrupu, m ir 0,1 vai 2, R11 un R12, kas ir vienādi vai dažādi, katrs ir ūdeņradis, alkilgrupa, arilgrupa vai aralkilgrupa un arilatlikums var būt aizvietots ar halogēnu, ciāngrupu, alkilgrupu, alkoksigrupu vai trifluor* metilgrupu, vai R11 un R12 kopā ar slāpekļa atomu veido ciklu: Hlī —'FVn
    0 5 4
    kur n ir 1 vai 2, R2 un R1 2 kopā ar slāpekļa atomu veido ciklu ar formulu 10 (CH2) 2' c -N (CH2>d 15 kur c un d ir ar iepriekš doto nozīmi un Y ir O, S vai grupa NR3 vai CH(CH2)e-NHR3, kur 20 R3 ir ar iepriekš doto nozīmi un e ir 0,1,2, 3 vai 4, un tā enantiomēri un fizioloģiski saderīgi sāļi ar nosacījumu, ka Q nevar būt neaizvietota 2-pirolilgrupa, 2-oksazolilgrupa, 5-oksazolilgrupa vai 2-imidazolilgrupa. 25
  2. 2. Savienojums saskaņā ar 1. punktu, kur Q ir COR1. 1 Savienojums saskaņā ar 2. punktu, kur R1 ir CH3, C2H5, C3H7, C4H9, CgH,,, ciklopropilgrupa, metilciklopropilgrupa, ciklobutilgrupa, metilciklobutilgrupa. 30 2 Savienojums saskaņā ar 1. punktu, kur Q ir fenilgrupa, fluorfenilgrupa. 3 Savienojums saskaņā ar 1. punktu, kur Q ir tienilgrupa vai furanilgrupa.
  3. 6. Savienojums saskaņā ar jebkuru no 1. līdz 5. punktam, kur R1 ir C^Cgalkil- grupa. 5 LV 11736
  4. 7. Savienojums saskaņā ar jebkuru no 1. līdz 6. punktam, kurZ ir ūdeņradis. 8. 5 9. Savienojums saskaņā ar jebkuru no 1. līdz 6. punktam, kurZ ir halogēns,. Savienojums saskaņā ar 8. punktu, kur Z ir fluors.
  5. 10. Savienojums 8-acetil-2-(dipropilamino)tetralīns, tā enantiomēri un 11. fizioloģiski saderīgi sali. Savienojums 8-fenil-2-(dipropilamino)tetralīns, tā enantiomēri un fizioloģiski saderīgi sāļi.
  6. 12. Savienojums 8-(2-furanil)-2-(dipropilamino)tetralīns, tā enantiomēri un 15 fizioloģiski saderigi sāļi. 13. Farmaceitisks preparāts, kas kā aktīvo sastāvdaļu satur savienojumu saskaņā ar jebkuru no 1. līdz 12. punktam, tā enantiomēru vai fizioloģiski sadengu sāli. 20 14. Savienojums, kā noteikts jebkurā no 1. līdz 12. punktam, tā enantiomērs vai fizioloģiski saderīgs sāls izmantošanai terapijā. 15. 25 Savienojums saskaņā ar 14. punktu izmantošanai depresijas, nemiera, anoreksijas, vecuma plānprātības, migrēnas, Alcheimera slimības, hipertensijas, termoregulācijas un seksuālu traucējumu ārstēšanā. 16. Savienojums saskaņā ar 14. punktu izmantošanai sāpju ārstēšanā. 30 17. Savienojums saskaņā ar 14. punktu izmantošanai traucējumu ārstēšanā sirds un asinsvadu sistēmā. 18. Savienojuma saskaņā ar jebkuru no 1. līdz 12. punktam izmantošana medikamenta ražošanai traucējumu ārstēšanai centrālajā nervu sistēmā, 35 sevišķi 5-hidroksitriptamīna izraisītu traucējumu ārstēšanā. 6
  7. 19. Izmantošana saskaņā ar 18. punktu medikamenta ražošanai depresijas, nemiera, hipertensijas, anoreksijas, vecuma plānprātības, migrēnas, Alcheimera slimības, termoregulācijas un seksuālu traucējumu ārstēšanai.
  8. 20. Izmantošana saskaņā ar 18. punktu medikamenta ražošanai sāpju ārstēšanai.
  9. 21. Izmantošana saskaņā ar 18. punktu medikamenta ražošanai traucējumu ārstēšanai sirds un asinsvadu sistēmā.
  10. 22. Metode savienojuma ar formulu (I) saskaņā ar 1. punktu izgatavošanai a) pārvēršot savienojumu ar formulu (II)
    (II) kur X ir atšķeļama grupa un R, R2 un R3 ir, kā norādīts zem formulas (I), katalītiskā ciklā, izmantojot nulles vērtības pārejas metālu M°, kas tiek pakļauts oksidatīvai piesaistīšanai anl-X-saitēm, apstrādei ar oglekļa monooksīdu ar sekojošu metāla pāreju starp R1-M1, kur M1 ir metāls un R1 ir, kā norādīts zem formulas (I), un sākumā iegūto karbonilēto σ-aril- metāl-X-kompleksu, lai iegūtu savienojumu ar formulu (I); b) reakcijā katalītiskā ciklā, izmantojot nulles vērtības pārejas metālu M°, kas tiek pakļauts oksidatīvai piesaistīšanai R1-X, kur R1 ir, kā norādīts zem formulas (I), un X ir atmetama grupa, apstrādei ar oglekļa monooksīdu un tālāk pievienojot savienojumu ar formulu (III)
    H (III) 7 LV 11736 kur R, R2 un R3 ir, kā norādīts zem formulas (I), un M1 ir pārejas metāls, lai iegūtu savienojumu ar formulu (I); c) pārvēršot savienojumu ar formulu (II)
    kur X ir atšķeļama grupa un R, R2 un R3 ir, kā norādīts zem formulas (I), liekot reaģēt ar nulles vērtības pārejas metālu M° un piemērotu arilaizvietotāju, piemēram, trialkilarilstannāngrupu, lai iegūtu savienojumu ar formulu (IB); d) pārvēršot savienojumu ar formulu (V)
    (i) kur X ir atšķeļama grupa, piemēram, trifluormetānsulfonātgrupa, Z ir halogēns, R, R2 un R3 ir, kā norādīts zem formulas (I), reakcijās, kas aprakstītas iepriekš metodēs a, b, un c, lai iegūtu savienojumu ar formulu (i); e) pārvēršot savienojumu ar formulu (IV)
    (IV) δ kur R, R2 un R3 ir, kā norādīts zem formulas (I), apstrādājot ar metālorganisku reaģentu un tālāk hidrolizējot, lai iegūtu savienojumu ar formulu (I), pēc kā iegūtā bāze neobligāti tiek pārvērsta par fizioloģiski saderīgu pievienotas skābes sāli vai iegūtais sāls tiek pārvērsts par bāzi 5 vai citu fizioloģiski saderigu pievienotas skābes sāli un neobligāti iegūtais izomēru maisījums tiek sadalīts līdz tīram izomēram.
LVP-96-420A 1989-05-26 1996-11-01 Novel 8-substituted-2-amino-tetralines LV11736B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8901889A SE8901889D0 (sv) 1989-05-26 1989-05-26 Novel 8-substituted-2-aminotetralines

Publications (2)

Publication Number Publication Date
LV11736A LV11736A (lv) 1997-04-20
LV11736B true LV11736B (en) 1997-10-20

Family

ID=20376074

Family Applications (2)

Application Number Title Priority Date Filing Date
LVP-93-869A LV10243B (en) 1989-05-26 1993-06-30 Novel 8-substituted-2-aminotetralines
LVP-96-420A LV11736B (en) 1989-05-26 1996-11-01 Novel 8-substituted-2-amino-tetralines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LVP-93-869A LV10243B (en) 1989-05-26 1993-06-30 Novel 8-substituted-2-aminotetralines

Country Status (41)

Country Link
US (1) US5635537A (lv)
EP (1) EP0399982B1 (lv)
JP (1) JP2818692B2 (lv)
KR (1) KR100193981B1 (lv)
CN (1) CN1023399C (lv)
AT (1) ATE129696T1 (lv)
AU (1) AU644081B2 (lv)
CA (1) CA2032498C (lv)
CY (1) CY1989A (lv)
CZ (1) CZ286038B6 (lv)
DD (1) DD298909A5 (lv)
DE (1) DE69023274T2 (lv)
DK (1) DK0399982T3 (lv)
DZ (1) DZ1417A1 (lv)
ES (1) ES2078962T3 (lv)
FI (1) FI114151B (lv)
GR (1) GR3018566T3 (lv)
HK (1) HK55697A (lv)
HR (1) HRP920622B1 (lv)
HU (2) HUT58685A (lv)
IE (1) IE75057B1 (lv)
IL (1) IL94428A (lv)
IS (1) IS1663B (lv)
JO (1) JO1617B1 (lv)
LT (1) LT3966B (lv)
LV (2) LV10243B (lv)
MX (1) MX20842A (lv)
NO (1) NO176603C (lv)
NZ (1) NZ233724A (lv)
PH (1) PH31110A (lv)
PL (2) PL164245B1 (lv)
PT (1) PT94163B (lv)
RU (1) RU2093507C1 (lv)
SA (1) SA90100274B1 (lv)
SE (1) SE8901889D0 (lv)
SI (1) SI9011006B (lv)
SK (1) SK280731B6 (lv)
UA (1) UA40562C2 (lv)
WO (1) WO1990014330A1 (lv)
YU (1) YU48830B (lv)
ZA (1) ZA903801B (lv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086535C1 (ru) * 1989-05-31 1997-08-10 Дзе Апджон Компани Производные 1,2,3,4-тетрагидро-2-нафтиламина
ES2100211T3 (es) * 1990-08-15 1997-06-16 Lilly Co Eli 2-amino-1,2,3,4-tetrahidronaftalenos, 3-aminocromanos y 3-aminotiocromanos sustituidos en el anillo.
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
ATE197145T1 (de) * 1991-02-08 2000-11-15 Lilly Co Eli Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphtahline und 3-aminochromane
US5347013A (en) * 1991-03-28 1994-09-13 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[cd]indoles
US5244911A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz(cd)indoles and pharmaceutical use thereof
US5244912A (en) * 1991-03-28 1993-09-14 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz(cd)indoles and pharmaceutical use thereof
US5643934A (en) * 1991-03-28 1997-07-01 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz [CD]indoles
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
SE9103745D0 (sv) * 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
SE9301732D0 (sv) * 1993-05-18 1993-05-18 Haakan Wilhelm Wikstroem New centrally acting 5-,6-,7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins
WO1996015099A1 (en) * 1994-11-09 1996-05-23 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
GB9509156D0 (en) * 1995-05-05 1995-06-28 Sandoz Ltd Organic compounds
CN104276955A (zh) 2006-01-06 2015-01-14 赛诺维信制药公司 基于四氢萘酮的单胺再摄取抑制剂
JP2024511078A (ja) 2021-03-17 2024-03-12 レセプトス エルエルシー 抗ｉｌ－１３抗体を用いてアトピー性皮膚炎を処置する方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2752659A1 (de) * 1976-12-07 1978-06-08 Sandoz Ag Neue tetralinderivate, ihre herstellung und verwendung
US4247907A (en) * 1978-11-27 1981-01-27 International Business Machines Corporation Method and apparatus for typing characters and optically readable binary representations thereof on same page
SE8004002L (sv) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
IL65501A (en) * 1981-05-08 1986-04-29 Astra Laekemedel Ab 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them
DE3479314D1 (en) * 1984-05-22 1989-09-14 Nelson Res & Dev Substituted 2-aminotetralins and processes for synthesis
ATE38029T1 (de) * 1985-06-26 1988-11-15 Smithkline Beckman Corp Benz-trisubstituierte 2-aminotetraline.
IL79323A (en) * 1985-07-10 1990-03-19 Sanofi Sa Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them
DE3718317A1 (de) * 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
DK0452390T3 (da) * 1989-01-09 1995-04-03 Upjohn Co Halogensubstituerede aminotetraliner
RU2086535C1 (ru) * 1989-05-31 1997-08-10 Дзе Апджон Компани Производные 1,2,3,4-тетрагидро-2-нафтиламина

Also Published As

Publication number Publication date
LTIP1723A (en) 1995-08-25
YU100690A (en) 1992-05-28
CN1023399C (zh) 1994-01-05
HU904810D0 (en) 1991-06-28
FI910381A0 (fi) 1991-01-25
CA2032498C (en) 2002-03-26
IS3580A7 (is) 1990-11-27
NO910310D0 (no) 1991-01-25
MX20842A (es) 1993-11-01
ZA903801B (en) 1991-01-30
PL285330A1 (en) 1991-11-04
NO910310L (no) 1991-01-25
CA2032498A1 (en) 1990-11-27
RU2093507C1 (ru) 1997-10-20
NZ233724A (en) 1993-01-27
IL94428A0 (en) 1991-03-10
EP0399982A1 (en) 1990-11-28
ATE129696T1 (de) 1995-11-15
KR100193981B1 (ko) 1999-06-15
HU211880A9 (en) 1995-12-28
UA40562C2 (uk) 2001-08-15
PT94163B (pt) 1996-12-31
EP0399982B1 (en) 1995-11-02
US5635537A (en) 1997-06-03
JP2818692B2 (ja) 1998-10-30
CZ286038B6 (cs) 1999-12-15
PH31110A (en) 1998-02-23
ES2078962T3 (es) 1996-01-01
JO1617B1 (en) 1991-11-27
LT3966B (en) 1996-05-27
PL165166B1 (pl) 1994-11-30
HUT58685A (en) 1992-03-30
IE75057B1 (en) 1997-08-27
AU644081B2 (en) 1993-12-02
DK0399982T3 (da) 1996-03-04
CY1989A (en) 1997-09-05
DE69023274T2 (de) 1996-04-11
DD298909A5 (de) 1992-03-19
SE8901889D0 (sv) 1989-05-26
HRP920622A2 (en) 1998-06-30
CN1047494A (zh) 1990-12-05
LV10243B (en) 1995-04-20
PT94163A (pt) 1991-01-08
SI9011006B (sl) 1998-12-31
LV11736A (lv) 1997-04-20
SA90100274B1 (ar) 2005-06-01
JPH04500362A (ja) 1992-01-23
YU48830B (sh) 2002-03-18
HK55697A (en) 1997-05-09
SK256090A3 (en) 2000-07-11
IS1663B (is) 1997-07-04
IE901833L (en) 1990-11-26
NO176603C (no) 1995-05-03
DE69023274D1 (de) 1995-12-07
GR3018566T3 (en) 1996-03-31
FI114151B (fi) 2004-08-31
NO176603B (no) 1995-01-23
CZ256090A3 (cs) 1999-10-13
SK280731B6 (sk) 2000-07-11
LV10243A (lv) 1994-10-20
PL164245B1 (pl) 1994-07-29
KR920701121A (ko) 1992-08-11
HRP920622B1 (en) 2000-04-30
SI9011006A (en) 1997-12-31
IL94428A (en) 1995-12-31
DZ1417A1 (fr) 2004-09-13
AU5818590A (en) 1990-12-18
WO1990014330A1 (en) 1990-11-29

Similar Documents

Publication Publication Date Title
LV11736B (en) Novel 8-substituted-2-amino-tetralines
JP2750187B2 (ja) 治療上有効なテトラリン誘導体
LV10449B (en) New chroman and thiochroman derivatives
EP1096926B1 (en) Methods and compounds for treating depression
CZ231397A3 (cs) 2-Aminoindany jako selektivní dopaminové D3 ligandy
JPH11263761A (ja) 新規なナフタレン化合物、それらの製造方法、及びそれらを含む医薬組成物
US5376687A (en) Bicyclic amino-substituted compounds
IE902313A1 (en) 2-amino-1,2,3,4-tetrahydronaphthalene derivatives with¹cardiovascular activity, process for their preparation and¹pharmaceutical compositions containing them
FR2833010A1 (fr) Propanolaminomethyltetralines, leur preparation et compositions pharmaceutiques les contenant
JP2000500748A (ja) 興奮性アミノ酸誘導体
EP1790337A2 (en) Methods and compounds for treating depression and other disorders